drugset / Trial / NCT05168007
Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia
RandomizedParallel-groupDouble-blindTreatment
Summary
This Study is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/day and 6 mg/day in Patients with Acute Psychotic Episode of Schizophrenia.
Timeline
- Start
- 2021-11-19
- Primary completion
- 2023-07-17
- Completion
- 2023-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cariprazine | Small molecule | 3 mg | — |
| Subject | Cariprazine | Small molecule | 6 mg | — |